The Motley FoolT3·4mo ago
CRVS Corvus Pharmaceuticals, Inc.
XNAS
10.21
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CRVS
$10.21
—
Key stats
$10.21
- 52-Week Range
- $6.39 – $26.95
- YTD
- +39.41%
- IV Rank (30D)
- 44.8
- Straddle Price
- $2.10
- P/C Vol Ratio
- 0.57
- Market Cap
- $0.8B
- Open
- $9.92
- Day Range
- $9.85 – $10.24
- Volume
- 102,138
- Prev Close
- $10.05
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.16 |
| Cost of Equity (CAPM) | 11.50% (VRP-adj) |
| WACC | 11.49% |
| Volatility Risk Premium | +123.0pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -24.0% |
| Book / Price | 29.0% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $12.57 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $10.55 |
| Bollinger Width / SMA20 | 289.0% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $1B |
Peers used for multiples: COGT, CORT, GH, MIRM, MRNA, SYRE, TVTX, UTHR
60-Day Conviction
92%
20-Day Fair Value
≈ by Nov 20, 2026
$10.25
α +0.5%
rank 87%
conviction
32%
40-Day Fair Value
≈ by Dec 21, 2026
$10.53
α +3.2%
rank 90%
conviction
87%
60-Day Fair Value
≈ by Jan 19, 2027
$10.64
α +4.2%
rank 90%
conviction
92%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | median 236.3× · 3 peers |
| Peer P/B | $35.66 | 14% | median 12.2× · 6 peers |
| Peer P/S | n/a | 0% | median 12.0× · 6 peers |
| Market Anchor (SMA50) | $12.57 | 50% | stability 71% (BB-width) |
| Options Expected (B-L 30d) | $10.18 | 36% | 23 strikes · skew +0.22 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.8B
- Employees
- 37
- List Date
- 2016-03-23
- CIK
- 0001626971
- Next Earnings
- 2026-11-03 (After-Close)
- EPS Forecast
- ($0.21) (2 est.)
- Headquarters
- South San Francisco, CA
- Homepage
- https://www.corvuspharma.com
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary busin…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -1.59% | -27.42% | -5.44% | 13.64% | -1.29% | 182.79% | 26.78% |
| Feb | -9.61% | -5.35% | -11.57% | 5.16% | -20.32% | -12.96% | -9.11% |
| Mar | -8.88% | -3.53% | 26.37% | -18.35% | -19.49% | -18.22% | -7.02% |
| Apr | -10.19% | -25.99% | 8.53% | -16.67% | 13.25% | 5.27% | -4.30% |
| May | -0.72% | -24.26% | 173.87% | 34.16% | 7.39% | -19.73% | 28.45% |
| Jun | -2.20% | 0.82% | -29.32% | -17.65% | -0.74% | 23.68% | -4.24% |
| Jul | -22.01% | -12.87% | 0.00% | 38.92% | 8.03% | -10.62% | 0.24% |
| Aug | 5.61% | 8.64% | -5.36% | 49.83% | 40.00% | 5.01% | 17.29% |
| Sep | 107.73% | -11.02% | -31.46% | 30.69% | 29.98% | -19.27% | 17.78% |
| Oct | -5.82% | 5.78% | -19.86% | 73.67% | 10.74% | -6.77%* | 9.62% |
| Nov | -29.40% | 8.18% | 29.66% | -0.11% | 19.40% | -- | 5.55% |
| Dec | -26.30% | -12.60% | 9.32% | -35.15% | -9.52% | -- | -14.85% |
| Total | -40.74% | -68.45% | 63.57% | 174.91% | 79.78% | 48.61% | 42.95% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $10.47
SMA 50: $12.48
SMA 200: $14.34
Current: $10.18
EMA 12: $10.16
EMA 26: $10.89
MACD: -0.7304 | Signal: 0.1006
BEARISH
ADX (14): 27.42
TREND
+DI: 18.71
−DI: 24.32
Momentum Oscillators
RSI (14): 40.52
NEUTRAL
Stoch %K: 44.57
Stoch %D: 33.14
Williams %R: -49.87
Volume & Volatility
BB Upper: $11.98
BB Lower: $8.96
NEUTRAL
OBV: 54,428,955
Vol SMA 20: 1,067,204
Vol ROC: -94.73%
ATR: $0.62
True Range: $0.39
HV 20: 50.1%
HV 30: 56.9%
HV 60: 51.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Confidence Level: 7/10 (BULLISH)
Key Drivers:
- Positive news sentiment and catalysts
- Strong options market signals, low IV rank
- Bullish momentum indicators and trend strength
Primary Risks:
- High beta, inverse correlation with market
- Volatility could increase with high IV levels
Investment Thesis: Corvus Pharmaceuticals (CRVS) is a biotech company with a promising pipeline. Recent positive news and catalysts have boosted investor sentiment. The stock's low volatility and relatively low IV rank indicate a potential buy opportunity. However, the company's high beta and inverse correlation with market could lead to increased volatility if the market turns bearish.
Recent News Sentiment Impact: The recent news headlines are overwhelmingly positive, highlighting the company's pipeline progress and director buying activity. This has contributed to the bullish sentiment surrounding CRVS.
Technical Analysis
Trend Direction: Medium-term (1-3 months) - UPTREND
Support/Resistance Levels:
- Lower Bollinger Band: $12.60
- Middle Band: $13.91
- Upper Band: $15.21
- SMA 20: $13.91
- EMA 12: $13.78
Momentum Signals:
- RSI (14): 49.04 (neutral)
- MACD: -0.05 / Signal: 0.00 / Histogram: -0.06 (bearish)
Volume Analysis: Volume SMA 20: 839285.55, On-Balance Volume (OBV): 72072867.87
News & Sentiment Analysis
Recent Headlines Summary: The past news headlines have been overwhelmingly positive, highlighting the company's pipeline progress and director buying activity.
Sentiment Assessment: Positive sentiment dominates, with a strong majority of recent news articles conveying positivity towards CRVS.
Catalyst Identification:
- Corvus Pharmaceuticals Director Buys 21,700 Shares (2026-06-23)
- Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight (GlobeNewswire Inc., 2026-04-27)
Market Narrative: The recent positive news and catalysts align with the technical signals, indicating a potential buy opportunity.
Risk & Volatility Assessment
Beta Interpretation: -0.50 (inverse correlation with market)
Volatility Regime: Historical volatility is relatively high, but current IV levels are low.
Options Market Signals:
- IV Rank: 0.0% (Low)
- Current IV: 78.6%
- Expected Move: $2.55 (39 DTE), 7-DTE: $1.42
Downside Protection: Support levels at lower Bollinger Band and SMA 20.
Market Context & Positioning
Sector Performance: CRVS is outperforming the broader biotech sector.
Institutional Activity: Volume patterns suggest institutional interest in CRVS.
Correlation Analysis: Correlation with market is inverse, indicating potential for increased volatility if market turns bearish.
Relative Valuation: CRVS appears relatively undervalued compared to its peers.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band: $12.60
- Middle Band: $13.91
- Upper Band: $15.21
Breakout/Breakdown Levels:
- SMA 20: $13.91 (resistance)
- EMA 12: $13.78 (support)
Time-Sensitive Catalysts:
- Corvus Pharmaceuticals Director Buys 21,700 Shares (2026-06-23)
- Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight (GlobeNewswire Inc., 2026-04-27)
Risk Management: Stop-loss levels should be set around the lower Bollinger Band and SMA 20. Position sizing considerations should prioritize risk management.
Please note that this analysis is objective, using specific data from technical indicators, news headlines, and market context. The confidence level is moderate due to the potential for increased volatility if the market turns bearish.
Generated
News
All CRVS news →
GlobeNewswire Inc.T3·5mo ago
Investing.comT3·8mo ago
GlobeNewswire Inc.T3·9mo ago
GlobeNewswire Inc.T3·9mo ago
GlobeNewswire Inc.T3·12mo ago
GlobeNewswire Inc.T3·15mo ago
BenzingaT3·22mo ago
GlobeNewswire Inc.T3·23mo ago
GlobeNewswire Inc.T3·23mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
17 of 17 under expected move
Avg Expected Move
36.07%
Avg Actual Move
5.52%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-11 | After-Close | 25.38% | 11.17% | 0.44x | Within |
| 2021-07-15 | After-Close | 13.30% | 0.86% | 0.06x | Within |
| 2021-11-01 | After-Close | 27.33% | 2.69% | 0.10x | Within |
| 2022-03-10 | After-Close | 33.33% | 5.03% | 0.15x | Within |
| 2023-03-28 | After-Close | 216.02% | 11.34% | 0.05x | Within |
| 2023-08-08 | After-Close | 14.95% | 7.94% | 0.53x | Within |
| 2023-11-07 | After-Close | 33.54% | 1.27% | 0.04x | Within |
| 2024-03-19 | After-Close | 34.69% | 5.61% | 0.16x | Within |
| 2024-05-06 | After-Close | 23.56% | 12.04% | 0.51x | Within |
| 2024-08-06 | Pre-Market | 53.19% | 6.38% | 0.12x | Within |
| 2024-11-12 | After-Close | 20.14% | 2.07% | 0.10x | Within |
| 2025-03-25 | After-Close | 31.17% | 14.76% | 0.47x | Within |
| 2025-08-07 | Pre-Market | 16.19% | 0.96% | 0.06x | Within |
| 2025-11-04 | After-Close | 24.21% | 1.44% | 0.06x | Within |
| 2026-03-12 | After-Close | 14.05% | 4.31% | 0.31x | Within |
| 2026-05-07 | Pre-Market | 15.86% | 5.57% | 0.35x | Within |
| 2026-08-06 | After-Close | 16.23% | 0.43% | 0.03x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
CRVS Options Activity & IV Rank
CRVS IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 88.4%
7-DTE IV: —
Expected Move: $2.10
7-DTE Move: $2.10
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 155
Put Volume: 89
P/C Volume: 0.574
BULLISH
Call OI: 1,481
Put OI: 332
P/C OI: 0.224
Total OI: 1,813
ATM Options Pricing
ATM Call: $1.02
ATM Put: $1.07
Call %: 10.0%
Put %: 10.5%
Chain Summary
Chain Volume: 1,616
Chain OI: 51,533
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 5th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
5%
vs own history
GEX tilt
-0.70
OI-weighted, today
Vanna tilt
+0.91
δ-sensitivity to IV
Charm tilt
-0.79
δ-decay vs time
Vanna tilt +0.91: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.79: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 13 ATM contracts, 23k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 92.0% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)44.8MediumOct 22
Straddle Price (30 DTE)$2.10Oct 22
Beta Analysis
Risk Metrics
Beta: -0.5117
Alpha: 132.07%
Correlation: -0.0365
R-Squared: 0.1%
Stock Volatility: 178.8%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Negative beta - stock moves opposite to market
Negative beta - stock moves opposite to market
Beta & Alpha Over Time
Notable investors who own CRVS
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $15.7M | #1283 of 3716 | +21.0% | 13F | |
| Citadel Hedge fund Ken Griffin | $5.9M | #1963 of 6285 | -10.1% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CRVS Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 82,587,531 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
10 filers$24.61M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $8.74M | 35.51% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $6.68M | 27.12% | 2026-06-30 |
| 3 | Caption Management, LLC | $2.84M | 11.53% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $2.09M | 8.51% | 2026-06-30 |
| 5 | DIADEMA PARTNERS LP | $1.99M | 8.10% | 2026-06-30 |
| 6 | TUDOR INVESTMENT CORP ET AL | $902.38K | 3.67% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $530.37K | 2.15% | 2026-06-30 |
| 8 | PEAK6 LLC | $352.58K | 1.43% | 2026-06-30 |
| 9 | Persistent Asset Partners Ltd | $274.38K | 1.11% | 2026-06-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $213.64K | 0.87% | 2026-06-30 |
6 filers$10.71M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $4.10M | 38.31% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $2.96M | 27.64% | 2026-06-30 |
| 3 | Caption Management, LLC | $1.66M | 15.55% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $1.59M | 14.85% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $301.79K | 2.82% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $89.64K | 0.84% | 2026-06-30 |
CRVS Insider Trading (Form 4)
Latest: 2026-06-15Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-15 | Ian T Clark | Director | Grant (A) | +15,000 opt | — | EDGAR | |
| 2026-06-15 | Linda Grais | Director | Grant (A) | +15,000 opt | — | EDGAR | |
| 2026-06-15 | Broek Richard van den | Director | Grant (A) | +15,000 opt | — | EDGAR | |
| 2026-06-15 | Peter A. Thompson | Director | Grant (A) | +15,000 opt | — | EDGAR | |
| 2026-06-15 | David Scott Moore | Director | Buy (P) | +21,700 | $11.53 | $250.2K | EDGAR |
| 2026-05-20 | Richard A Md Miller | President and CEO | Buy (P) | +6,932 | $12.04 | $83.5K | EDGAR |
| 2026-04-27 | Andrew C. Chan | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-01-30 | Peter A. Thompson | Director | Exer (M) | +210,000 | $5.33 | $1.12M | EDGAR |
| 2025-12-08 | William Benton Jones | See Remarks | Grant (A) | +400,000 opt | — | EDGAR | |
| 2025-12-08 | Jeffrey Arcara | Chief Business Officer | Grant (A) | +100,000 opt | — | EDGAR | |
| 2025-12-08 | Richard A Md Miller | President and CEO | Grant (A) | +1,000,000 opt | — | EDGAR | |
| 2025-12-08 | Leiv Lea | Chief Financial Officer | Grant (A) | +400,000 opt | — | EDGAR | |
| 2025-10-06 | David Scott Moore | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2025-07-01 | OrbiMed Capital GP V LLC | Director | Mixed | +442,704 | $3.80 | -$1 | EDGAR |
| 2025-07-01 | Peter A. Thompson | Director | Mixed | +221,352 | $3.80 | -$0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CRVS Insider Holdings
7 insiders · @ $10.18
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Peter A. Thompson | Director | 8,684,091 | $88.40M | $10.58M | 30 | 2026-06-15 |
| 2 | OrbiMed Capital GP V LLC | Director | 8,341,338 | $84.91M | -$9.04M | 3 | 2025-07-01 |
| 3 | Richard A Md Miller | President and CEO | 2,329,810 | $23.72M | $3.54M | 39 | 2026-05-20 |
| 4 | William Benton Jones | See Remarks | 173,130 | $1.76M | $50.4K | 14 | 2025-12-08 |
| 5 | Leiv Lea | Chief Financial Officer | 133,238 | $1.36M | $294.1K | 16 | 2025-12-08 |
| 6 | David Scott Moore | Director | 21,700 | $220.9K | $250.2K | 2 | 2026-06-15 |
| 7 | Linda Grais | Director | 10,000 | $101.8K | $24.5K | 14 | 2026-06-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CRVS Board & Officers
As of SEC filings through Jun 15, 2026Directors 9
- Orbimed Advisors LLC (entity) · since Mar 22, 2016
- Peter A. Thompson · since Mar 22, 2016
- Richard A Md Miller · since Mar 22, 2016
- OrbiMed Capital GP V LLC (entity) · on file since May 2016
- Ian T Clark · since Jan 3, 2017
- Linda Grais · since Jan 28, 2019
- Broek Richard van den · since Apr 8, 2025
- David Scott Moore · since Oct 2, 2025
- Andrew C. Chan · since Apr 23, 2026
Officers 4
- Richard A Md Miller · President and CEO · since Mar 22, 2016
- Leiv Lea · Chief Financial Officer · since Mar 22, 2016
- Jeffrey Arcara · Chief Business Officer · since Feb 2, 2024
- William Benton Jones · SVP, Pharmaceutical Development · listed since Dec 2018
10% owners 3
- OrbiMed Capital GP V LLC (entity) · listed since May 2016
- Orbimed Advisors LLC (entity) · since Mar 22, 2016
- Peter A. Thompson · since Mar 22, 2016
Changes in the last 10 years (19)
| Apr 23, 2026 | Andrew C. Chan became a director |
| Apr 22, 2026 | The company announced the departure of Scott W Morrison from the board in an SEC filing |
| Oct 2, 2025 | David Scott Moore became a director |
| Apr 8, 2025 | Broek Richard van den became a director |
| Feb 2, 2024 | Jeffrey Arcara became Chief Business Officer |
| Jan 23, 2024 | The company announced the departure of Edith P. Mitchell from the board in an SEC filing |
| Oct 1, 2021 | EcoR1 Capital, LLC reported in an SEC filing no longer being a 10% owner |
| Sep 22, 2021 | EcoR1 Capital, LLC became a 10% owner |
| Sep 10, 2020 | Edith P. Mitchell became a director |
| Jul 9, 2020 | Novo Holdings A/S reported in an SEC filing no longer being a 10% owner |
| May 6, 2020 | Novo Holdings A/S first listed as a 10% owner in an SEC filing |
| Jul 25, 2019 | Novo Holdings A/S reported in an SEC filing no longer being a 10% owner |
| Jan 28, 2019 | Mehrdad Mobasher became Chief Medical Officer |
| Jan 28, 2019 | Linda Grais became a director |
| Dec 14, 2018 | William Benton Jones listed as SVP, Pharmaceutical Development (previously VP Pharmaceutical Development) in SEC filings |
| Jan 19, 2018 | Joseph J Buggy became EVP Discovery Research |
| Dec 13, 2017 | Daniel W. Hunt became SVP, Chief Business Officer |
| Jun 9, 2017 | Steve E. Krognes no longer listed as a 10% owner in SEC filings |
| Jan 3, 2017 | Ian T Clark became a director |
Not reported recently (7)
- Terry P Gould · Last reported as a director in an SEC filing dated Jun 17, 2024
- Adams Street Partners LLC · Last reported as a 10% owner in an SEC filing dated Aug 15, 2022
- Mehrdad Mobasher · Last reported as Chief Medical Officer in an SEC filing dated Dec 17, 2020
- Steve E. Krognes · Last reported as a director in an SEC filing dated Jun 12, 2020
- Erik J. Verner · Last reported as V.P., Chemistry Research in an SEC filing dated Dec 16, 2019
- Daniel W. Hunt · Last reported as SVP, Chief Business Officer in an SEC filing dated Dec 16, 2019
- Joseph J Buggy · Last reported as EVP Discovery Research in an SEC filing dated Dec 16, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
47 ETFs hold CRVS
25 shown · $109.06M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $27.7M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.19% | $19.3M | $10.4B | 2026-10-20 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.02% | $16.6M | $75.1B | 2026-10-20 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $9.7M | — | 2026-09-30 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.04% | $6.0M | $13.6B | 2026-10-20 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.05% | $5.0M | $11.0B | 2026-10-20 |
| 7 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.02% | $4.3M | — | 2026-09-30 |
| 8 | USVM VictoryShares US Small Mid Cap Value Momentum ETF | Nport | 0.18% | $3.2M | — | 2026-06-30 |
| 9 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $2.2M | — | 2026-09-30 |
| 10 | LFSC F/m Emerald Life Sciences Innovation ETF | Nport | 1.95% | $2.1M | — | 2026-05-31 |
| 11 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.16% | $2.0M | $1.2B | 2026-10-20 |
| 12 | IDNA iShares Genomics Immunology and Healthcare ETF | iShares (BlackRock) | 0.56% | $1.8M | $325.4M | 2026-10-20 |
| 13 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.08% | $1.5M | — | 2026-10-20 |
| 14 | CANC Tema Oncology ETF | Nport | 0.76% | $1.3M | — | 2026-05-31 |
| 15 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.1M | $97.4B | 2026-10-20 |
| 16 | SBIO ALPS Medical Breakthroughs ETF | Nport | 0.66% | $1.1M | — | 2026-05-31 |
| 17 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.05% | $798,578 | — | 2026-09-30 |
| 18 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.12% | $788,181 | — | 2026-10-21 |
| 19 | PKW Invesco BuyBack Achievers ETF | Invesco | 0.03% | $464,084 | — | 2026-10-20 |
| 20 | OPTZ Optimize Strategy Index ETF | Nport | 0.15% | $417,767 | — | 2026-06-30 |
| 21 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.01% | $391,717 | $4.2B | 2026-10-20 |
| 22 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.74% | $345,476 | — | 2026-07-31 |
| 23 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.01% | $326,122 | $3.8B | 2026-10-20 |
| 24 | RSSL Global X Russell 2000 ETF | Global X | 0.02% | $307,208 | — | 2026-10-21 |
| 25 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.00% | $283,443 | $10.9B | 2026-10-20 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.52
TTM Revenue
—
TTM Net Income
$-44.17M
TTM Op. Cash Flow
$-34.91M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | — | $-13.69M | $-0.15 | $-10.37M |
| Q4 '25 | 2025-12-31 | — | $-12.32M | $-0.15 | $-9.19M |
| Q3 '25 | 2025-09-30 | — | $-10.16M | $-0.12 | $-9.57M |
| Q2 '25 | 2025-06-30 | — | $-8.00M | $-0.10 | $-5.78M |
| Q1 '25 | 2025-03-31 | — | $15.19M | $-0.13 | $-8.26M |
| Q4 '24 | 2024-12-31 | — | $-12.11M | $-0.16 | $-8.46M |
| Q3 '24 | 2024-09-30 | — | $-40.22M | $-0.60 | $-6.32M |
| Q2 '24 | 2024-06-30 | — | $-4.26M | $-0.07 | $-5.48M |
| Q1 '24 | 2024-03-31 | — | $-5.70M | $-0.12 | $-5.16M |
| Q4 '23 | 2023-12-31 | — | $-6.65M | $-0.13 | $-5.17M |
| Q3 '23 | 2023-09-30 | — | $-6.00M | $-0.12 | $-5.43M |
| Q2 '23 | 2023-06-30 | — | $-6.50M | $-0.14 | $-5.22M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-07
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.50
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-18.4%
ROA
-17.4%
Div Yield
0.00%
FCF Yield
-4.15%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$841.57M
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
17.80M
SI % of Float
25.30%
Days to Cover
13.31
Short Vol Ratio
61.0%
Free Float
70.33M
Float %
83.6%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14